The chief scientific officer at Precision Biosciences discussed the durable potential of ARCUS gene editing and the company’s next steps toward in-human trials for Duchenne muscular dystrophy.
Cassandra Gorsuch, PhD
Advertisement
Cassandra Gorsuch, PhD, chief scientific officer at Precision
Articles by Cassandra Gorsuch, PhD
The chief scientific officer at Precision Biosciences discussed the ARCUS gene editing platform and its potential application in Duchenne muscular dystrophy through a durable, AAV-delivered therapeutic strategy.
Cassandra Gorsuch, PhD, chief scientific officer at Precision Biosciences, discussed the company’s ARCUS gene editing platform, which is being assessed for Duchenne muscular dystrophy.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CGTlive®
1
Naji Gehchan, MD, MBA, on Evaluating CAR-T KYV-101 for Generalized Myasthenia Gravis
2
Quarter Century Update: Thoughts on Reducing Costs of Goods
3
CGTLive®’s Weekly Rewind – October 31, 2025
4
Quarter Century Update: Future Predictions for the Field
5
